▟ Vinebot intrinsic value, daily

← back

GEHC GE HealthCare

healthcare · valued with opus medium conviction · deep-dived 2026-10-27

STRONG BUY
Intrinsic value$75.05
Price (at call)$71.98
Margin of safety +4.3%
vs market (rating basis) +54.9%

Steady imaging incumbent with modest margin upside; fairly priced, not a bargain at ~$72.

The story

GE HealthCare is a scaled incumbent in medical imaging, ultrasound, patient monitoring and pharmaceutical diagnostics, with a sticky installed base, a growing service annuity, and a radiopharma and contrast franchise that helps protect it. It is a mature business that has only recently been spun off. Growth is mid-single-digit, and the margin story is self-help: pricing, mix shift toward recurring revenue and new products such as photon-counting CT and theranostics tracers, offset by tariffs and weak China demand. There is room for modest operating margin expansion toward the high teens, not a step change.

Growth of 4% matches the roughly 4% five-year CAGR and an installed-base replacement cycle; terminal growth of 3% sits safely below the 4.99% risk-free rate. The target margin of 16.5% is a bit above the 15-16% historical band, reflecting mix and cost actions but discounted for tariffs and China. Marginal sales-to-capital of 1.4 is above the reported 1.04, which is depressed by spin-off goodwill, because incremental growth needs little capital. Beta of 0.95 sits near the 0.9 medtech anchor, nudged up for leverage of about $5.5B in net debt.

Value drivers

Revenue growth (Y1)4.0%
Terminal growth3.0%
Forecast horizon7y
Target operating margin16.5%
Years to target margin5
Sales-to-capital1.40
Beta0.95
Failure probability2.0%
Cost of capital (WACC)8.3%
Terminal WACC8.4%

Valuation bridge

PV of explicit FCFF12.47B
PV of terminal value28.07B
Equity value33.90B
÷ shares → per share$75.05

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 22.12B 4.0% 14.9% 2.57B 607.63M 1.96B 1.81B
2 22.97B 3.8% 15.3% 2.74B 605.60M 2.13B 1.82B
3 23.81B 3.7% 15.7% 2.91B 601.48M 2.31B 1.82B
4 24.64B 3.5% 16.1% 3.09B 595.19M 2.49B 1.81B
5 25.46B 3.3% 16.5% 3.27B 586.69M 2.68B 1.80B
6 26.27B 3.2% 16.5% 3.37B 575.93M 2.80B 1.74B
7 27.06B 3.0% 16.5% 3.47B 562.90M 2.91B 1.67B

Key risks

  • Tariff costs and China volume-based procurement compress imaging margins
  • Hospital capex slowdown or reimbursement pressure delays equipment replacement cycles
  • Competitive pressure from Siemens Healthineers and Philips in CT/MR plus execution risk in radiopharma pipeline

Catalysts

  • Photon-counting CT and AI-enabled imaging launches driving share gains and pricing
  • Pharmaceutical diagnostics growth from new PET tracers (e.g., Flyrcado) and theranostics adoption

History

DatePriceIntrinsicMoSRating
2026-10-27$71.98 $75.05 +4.3% STRONG BUY
2026-09-07$68.86 $74.19 +7.7% STRONG BUY
2026-07-16$63.20 $78.94 +24.9% STRONG BUY
2026-06-23$63.72 $81.85 +28.4% STRONG BUY